SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 7, 2011
HALOZYME THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
|(State or other Jurisdiction of Incorporation)||(Commission File Number)||(IRS Employer Identification No.)|
|11388 Sorrento Valley Road, San Diego, California
|(Address of Principal Executive Offices)||(Zip Code)|
Registrants telephone number, including area code: (858) 794-8889
|(Former name or former address if changed since last report.)|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|A.||the Amended and Restated Development and Supply Agreement dated February 13, 2007 (the Development and Supply Agreement),|
|B.||the Amended and Restated Exclusive Distribution Agreement dated February 13, 2007,|
|C.||the Amended and Restated Quality Agreement dated February 13, 2007, and|
|D.||the Enhanze License and Collaboration Agreement dated February 13, 2007.|
Item 8.01 Other Events.
Update on Ultrafast Insulin Program
Halozyme recently initiated an insulin pump study that utilizes its rHuPH20 hyaluronidase enzyme (PH20) combined with two commercially available mealtime insulin analogs: insulin aspart, the active ingredient in NovoLog®, and insulin glulisine, the active ingredient in Apidra®. Patients with type 1 diabetes enrolled in these pump studies will receive the insulin analog alone and the Analog-PH20 combination for three days each. Data for pharmacokinetic and glucodynamic measures as well as safety and tolerability will be collected and compared for each treatment.
Halozymes two Phase 2 Analog-PH20 treatment studies, one in type 1 diabetes patients and the other in type 2 patients, have completed patient enrollment with approximately 110 patients in each study.
Additional information about these trials can be found at clinicaltrials.gov.
Termination Agreement between Halozyme Inc., Baxter Healthcare Corporation and Baxter Healthcare S.A., effective as of January 7, 2011.
Halozyme Therapeutics, Inc. Investor Presentation, dated January 12, 2011.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|Halozyme Therapeutics, Inc.|
January 10, 2011
By: /s/ Kurt A. Gustafson
Kurt A. Gustafson
Vice President and Chief Financial Officer